FHTX
Foghorn Therapeutics Inc
2.00$
-4.8%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | – | – | – | 9,001.7% | 224.3% | 6,547.6% | 6,681.7% | 49,985.4% | 3,150.5% | 625.2% | 578.5% | 405.9% | 674.2% | 38.8% | 522.4% | 150.2% | 14.8% | 16.5% | 11.6% | 9.0% | 26.6% | – | 11.9% | 245.3% | 8.7% | 7.3% | – | – | |
| – | – | – | – | – | – | – | – | – | – | 100.0% | -124.3% | -6,447.6% | -6,581.7% | -49,885.4% | -3,050.5% | -525.2% | -478.5% | -305.9% | -574.2% | 100.0% | -422.4% | -50.2% | 85.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 88.1% | -145.3% | 91.3% | 92.7% | 100.0% | 42.7% | |
| – | – | – | – | – | – | – | – | – | – | 9,001.7% | 6,337.8% | 6,547.6% | 6,681.7% | 49,985.4% | 3,150.5% | 625.2% | 578.5% | 405.9% | 674.2% | 564.8% | 522.4% | 150.2% | 404.8% | 505.6% | 345.5% | 316.2% | 718.1% | 363.3% | 276.5% | 245.3% | 248.1% | 558.9% | 115.3% | 217.0% | |
| – | – | – | – | – | – | – | – | – | – | 1,427.4% | 1,816.3% | 1,639.9% | 1,755.6% | 14,165.9% | 888.1% | 184.1% | 171.6% | 120.1% | 187.9% | 162.8% | 150.0% | 47.5% | 121.7% | 152.7% | 106.3% | 89.3% | 222.4% | 121.6% | 90.8% | 81.6% | 73.5% | 201.4% | 39.5% | 71.8% | |
| – | – | – | – | – | – | – | – | – | – | 10,429.1% | 8,154.2% | 1,639.9% | 1,755.6% | 14,165.9% | 888.1% | 184.1% | 171.6% | 120.1% | 187.9% | 727.6% | 150.0% | 47.5% | 526.5% | 658.3% | 486.6% | 405.5% | 940.5% | 485.0% | 367.3% | 81.6% | 303.2% | 753.0% | 154.8% | 229.1% | |
| – | – | – | – | – | – | – | – | – | – | -10,329.1% | -8,278.5% | -8,087.4% | -8,337.3% | -64,051.2% | -3,938.6% | -709.3% | -650.1% | -426.0% | -762.1% | -627.6% | -572.4% | -97.7% | -441.3% | -558.3% | -386.6% | -305.5% | -840.5% | -385.0% | -279.2% | -226.9% | -211.9% | -660.3% | -54.8% | -186.4% | |
| – | – | – | – | – | – | – | – | – | – | 112.8% | 127.9% | 169.9% | 177.4% | 1,217.1% | 59.7% | 22.7% | 41.8% | 37.5% | 125.6% | 42.7% | – | – | 39.3% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -10,260.9% | -8,270.1% | -8,037.1% | -8,283.5% | -63,609.8% | -4,087.4% | -686.6% | -608.3% | -388.4% | -690.4% | -563.7% | -509.8% | -77.9% | -383.4% | -495.4% | -333.6% | -244.9% | -682.9% | -316.4% | -237.3% | -194.4% | -234.3% | -608.4% | -44.7% | -175.8% | |
| – | – | – | – | – | – | – | – | – | – | 10,250.8% | 8,171.0% | 220.3% | 231.2% | 1,658.5% | -13,839.5% | -22.7% | 41.8% | -37.5% | 125.4% | 10.5% | 16.8% | 4.2% | 34.4% | 15.7% | – | -9.0% | -27.7% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -10,260.9% | -8,270.1% | -8,037.1% | -8,283.5% | -63,609.8% | -4,087.4% | -686.6% | -608.3% | -388.4% | -690.4% | -574.3% | -526.6% | -82.1% | -417.9% | -495.4% | -333.6% | -244.9% | -682.9% | -316.4% | -237.3% | -194.4% | -234.3% | -608.4% | -44.7% | -175.8% | |
| – | – | – | – | – | – | – | – | – | – | -10,005.6% | -7,917.9% | -7,817.5% | -7,825.1% | -60,292.7% | -3,914.0% | -665.9% | -590.1% | -375.7% | -670.1% | -547.5% | -494.2% | -72.9% | -368.7% | -478.8% | -340.3% | -235.5% | -656.2% | -302.5% | -225.4% | -183.9% | -225.6% | -601.1% | -43.5% | -170.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.